← boardnext 2027-03next 2028-05next 2029-07
COGT
Cogent Biosciences, Inc.distress 6/10 · elevated risk$38.98-1%today-7% from 52w high
Oncology 2
Lead: advanced systemic mastocytosis
Revenue
pre-revenue
Liquidity
$241M
Runway
0.8 yrs
Shares 1y
+22%
Price & events
-1.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.4%
1D
+2.7%
1W
+7.3%
1M
+7.8%
3M
+6.3%
6M
+215.1%
1Y
+327.8%
2Y
+501.5%
5Y
+216.9%
All
Overview
- Market Cap
- $6.66B
- Enterprise Value
- $6.64B
- Volume
- 145.32K
- 52 Week Range
- $10.86 – $42.11
- Total Shares
- 170.87M
- Float Shares
- 160.86M
- Short %
- 9.62%
- % Held by Insiders
- 0.43%
- % Held by Institutions
- 112.94%
- RVOL
- 0.05x
- Beta
- 0.34
Pipeline stages · 6 programs
CGT4859
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
CGT4255
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
CGT6297
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
bezuclastinib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
CGT9486, Sunitinib, Midazolam
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Bezuclastinib Tablets (Formulation A), Bezuclastinib Tablets (Formulation B)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 6 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-03 Estimated 50% readout ~2027-04-15 | Phase 1/2 | CGT4859 | Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult, FGFR2 Gene Fusion/Rearrangement, FGFR2 Gene Amplification, FGFR2 Gene Short Variants, FGFR3 Gene Fusion/Rearrangement, FGFR3 Gene Amplification, FGFR3 Gene Short Variants, FGFR2 Genetic Alterations, FGFR3 Genetic Alterations, Advanced Solid Tumors | — | active not recruiting |
| 2028-05 Estimated 50% readout ~2028-05-31 | Phase 1 | CGT4255 | Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression, Non-Small Cell Lung Cancer, HER2 | — | recruiting |
| 2029-07 Estimated 50% readout ~2029-07-31 | Phase 1 | CGT6297 | PIK3CA Mutations, Advanced Solid Tumors, Adult, Endometrial Cancer, HR Positive/HER-2 Negative Breast Cancer, HER2-low Breast Cancer | — | recruiting |
| 2025-09-30 | Phase 3 | CGT9486, Sunitinib, Midazolam | Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer | 482 | recruiting |
| 2025-09-19 | Phase 2 | bezuclastinib | Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL), Aggressive Systemic Mastocytosis (ASM) | 140 | recruiting |
Show all 6 trials · 1 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-05-22 | Phase 2 | Bezuclastinib Tablets (Formulation A), Bezuclastinib Tablets (Formulation B) | SSM, Mastocytosis, Indolent, Mastocytosis, Systemic, Mastocytosis, ISM, BMM, Smoldering Systemic Mastocytosis, Bone Marrow Mastocytosis | 237 | active not recruiting |
Catalyst news & presentations · 10
- 2026-08-04Estimated 45%earningsEarningsEarnings releaseyahoo
- first half of 2026regulatory submissionFiled (NDA/BLA)bezuclastinib · Submit NDA for bezuclastinib in imatinib-resistant or intolerant GISTSEC 8-K
- first half of 2026conferencedata presentationsecondarybezuclastinib · Present detailed APEX trial data at scientific meetingSEC 8-K
- before the end of 2025readoutPhase 3bezuclastinib · Top-line results from PEAK trialSEC 8-K
- by the end of 2025regulatory submissionFiled (NDA/BLA)bezuclastinib · NDA submission to FDA for bezuclastinib in NonAdvSMSEC 8-K
- ASH 2025conferencedata presentationsecondaryJAK2 V617F inhibitor · Initial data from novel JAK2 V617F inhibitorSEC 8-K
- July 2025readoutPhase 2bezuclastinib · Top-line results from SUMMIT Part 2.SEC 8-K
- mid-2025readoutPhase 2bezuclastinib · Top-line results from APEX Part 2.SEC 8-K
- 2025-06-11partnershipEntered into loan and security agreement with SLR Capital Partners for up to $400 million, initial $50 million drawn.SEC 8-K
- Q1 2025enrollment completesecondaryPhase 2bezuclastinib · Enrollment target for APEX Part 2.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $54 (+39% upside) · 12 analysts
- 2026-05-29WedbushOutperform
- 2026-05-06HC Wainwright & Co.Buy
- 2026-03-17WedbushOutperform
- 2026-02-18Piper SandlerOverweight
- 2026-01-21WedbushOutperform
- 2026-01-06HC Wainwright & Co.Buy
Competitors — advanced systemic mastocytosis
- none identified
Recent news
- 2026-07-23(COGT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
- 2026-07-15Cogent Bioscience (COGT) Files New Drug Application For Bezuclastinib - Yahoo Finance
- 2026-07-11Price to sales forward of Cogent Biosciences, Inc. – NASDAQ:COGT - TradingView
- 2026-07-11(COGT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
- 2026-07-11(COGT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
- 2026-07-10Cogent Biosciences (COGT) Files FDA Application As Bezuclastinib Hype Meets A Pricey Valuation - simplywall.st
- 2026-07-10FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Canc - Business Wire
- 2026-07-10Cogent Biosciences (COGT) Files FDA Application As Bezuclastinib Hype Meets A Pricey Valuation - Sahm
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.